Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $65.43, Implies 157% Upside

• According to estimates from 14 analysts, Rapport Therapeutics, Inc. stock's average price target has fallen from $68.29 to $65.43, with forecasts ranging from $50 to $89 per share
• Based on the Nov. 3 closing price, the updated target implies approximately 157% potential upside
• Consensus rating remains at “Buy” across 16 covering analysts, with 16 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Rapport Therapeutics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Rapport Therapeutics, Inc. in the dedicated News Flow.